HealthDay - TUESDAY, Jan. 10 (HealthDay News) -- Dutch researchers report disappointing results from an early clinical trial of the drug Nexavar (sorafenib) in fighting a tough-to-treat form of lung cancer.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.